Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Tuberous Sclerosis 6 Seizures 5 Marijuana Abuse 3 Lennox Gastaut Syndrome 3 Epilepsies, Myoclonic 3 Colonic Neoplasms 3 Breast Neoplasms 3 Sturge-Weber Syndrome 2 Neoplasms 2 Nausea 2 Glioblastoma 2 Anxiety Disorders 2 Vomiting 1 Tuberous Sclerosis 2 1 Tuberous Sclerosis 1 1 Spasms, Infantile 1 Solid Tumor 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Parasomnias 1 Pancreatic Neoplasms 1 Pain 1 Multiple Myeloma 1 Liver Neoplasms 1 Liver Cirrhosis 1 Gallbladder Neoplasms 1 Epilepsy 1 Dysgeusia 1 Drug Resistant Epilepsy 1 Colorectal Neoplasms 1

Interventions

Sorafenib 222 lenvatinib 147 Bevacizumab 131 Nivolumab 87 atezolizumab 81 pembrolizumab 74 Radiosurgery 71 durvalumab 63 sintilimab 61 Oxaliplatin 60 Fluorouracil 56 Doxorubicin 47 tislelizumab 46 apatinib 45 Radiofrequency Ablation 44 Hepatectomy 43 camrelizumab 41 Leucovorin 41 Radiotherapy 40 tremelimumab 37 Magnetic Resonance Spectroscopy 36 regorafenib 34 Capecitabine 30 Immune Checkpoint Inhibitors 29 Folfox protocol 29 Cisplatin 28 cabozantinib 26 Gemcitabine 26 Cyclophosphamide 26 Ipilimumab 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × Cannabidiol × Clear all

NCT06518434 2024-07-24

CanHep

University Medical Center Groningen

Phase 2 Recruiting

Gastrointestinal

Marijuana Abuse, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡